Navigation Links
Genetic research unveils common origins for distinct clinical diagnoses
Date:3/9/2008

Researchers at Johns Hopkins have discovered that two clinically different inherited syndromes are in fact variations of the same disorder. Reporting in the April issue of Nature Genetics, the team suggests that at least for this class of disorders, the total number and strength of genetic alterations an individual carries throughout the genome can generate a range of symptoms wide enough to appear like different conditions.

Were finally beginning to blur the boundaries encompassing some of these diseases by showing that they share the same molecular underpinnings, says Nicholas Katsanis, Ph.D., an associate professor of ophthalmology at the McKusick-Nathans Institute of Genetic Medicine at Hopkins. This is important progress for several reasons. First, knowing whats going on molecularly and being able to integrate rarer conditions under common mechanisms allows us to potentially help more people at once. Second, clinicians can finally begin to offer more accurate diagnoses based on what really matters: the state of affairs at the cellular/biochemical level. In time, this will empower genetic counseling and much improved patient management.

Katsaniss team studies Bardet-Biedl syndrome (BBS), a rare so-called ciliopathy that is characterized by a combination of vision loss, obesity, diabetes, extra digits and mental defects and caused by faulty cilia, tiny hairlike projections found on almost every cell of the body. Recently they started looking at another disease, Meckel-Gruber syndrome (MKS), which also shows cilia dysfunction but is clinically distinct from BBS and generally associated with prenatal or newborn death.

While these two groups of patients exhibit such different clinical outcomes, the genes associated with both syndromes all seemed to be pointing at the same culprit: cilia, says Katsanis. So we wondered if BBS and MKS might actually represent different flavors of the same disease.

The researchers sequenced the MKS genes from 200 BBS patients and found six families that, in addition to carrying BBS genetic mutations, also carried mutations in MKS genes. To figure out what, if any, effect these MKS mutations have on BBS, the team used a system they previously developed in zebrafish.

Knocking out BBS genes in zebrafish generates short fish with even shorter tails, among other malformations. Injecting normal BBS genes into these fish rescues them, resulting in normal looking fish.

The researchers reasoned that if MKS and BBS are indeed the same condition, then fish with the MKS genes knocked out should mimic the BBS knockout fish. They did. The team then went on to test mutant versions of MKS genes in BBS fish and found that three genes originally attributed to MKS do indeed cause BBS or render the BBS defects more pronounced, increasing the number of BBS genes to 14 in total.

From a clinical perspective, these two syndromes look nothing alike, but molecularly, the genes involved clearly participate in the same fundamental processes, says Katsanis. This means that Meckel-Gruber and Bardet-Biedel actually represent a continuum of one disease. This never would have been discovered in the clinic-only molecular analysis can reveal these things.

But what does this mean for clinicians and the diagnosis and treatment of these syndromes" Katsanis hopes that the growing body of molecular data will help move medicine away from symptom-defined syndromes, which can leave clinicians struggling with ambiguous diagnoses, to approaching disorders from a molecular standpoint. We now have the possibility of merging several rare disorders, he says. And their gross sum now turns out to be fairly common; hopefully this will now put them on the radar for drug development and other therapies.


'/>"/>

Contact: Audrey Huang
audrey@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. New stem cell technique improves genetic alteration
2. Einstein researchers genetically engineer immune cells into potent weapons for battling HIV
3. Genetic Test Predicts Response to Warfarin
4. New revelations in epigenetic control shed light on breast cancer
5. Researchers identify new genetic marker for breast cancer
6. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
7. Adult stem cell changes underlie rare genetic disease associated with accelerated aging
8. Genetic Factors for Smoking Boost Chronic Bronchitis Risk
9. Genetic factors in smoking also increase risk of chronic bronchitis
10. Dr. Robert Leonard First in New England to Offer Genetic Test for Male Pattern Baldness
11. U of Minn researchers discover genetic cancer link between humans and dogs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... Illustrate, Maintain® methodology and industry-leading compliance software, The Guard®, has helped another long-time ... Rights (OCR) HIPAA audit and properly satisfy the law. , Thanks to the ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... and social campaign, “Humans With Vaginas.” The goal is to ignite conversation via ... non-toxic personal care products. The brand has declared September “Humans with Vaginas” month, ...
(Date:9/20/2017)... ... 20, 2017 , ... Medicare doesn’t have the authority to ... for their prescription drugs, according to a new comparison of drug plans by ... behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive ... he emotionally pens his aspirations and goals to better one’s life through God. “The ... Green, while searching in all the wrong places, found a love for writing. Green ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm CORDA Investment ... 8, and Monday, September 11, off work and rolled up their sleeves to help ... to local homes to start the process of rebuilding. , CORDA founder Bonner C. ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
Breaking Medicine Technology: